Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
Apollo Global is in talks to acquire Johnson & Johnson’s orthopedics unit, Bloomberg News reports. The potential deal would test Apollo’s ability to deploy capital into a healthcare asset while adding transaction and execution risk before terms are known.
Bloomberg News reported that Apollo Global is in talks to acquire an orthopedics unit from Johnson & Johnson. The report does not disclose a purchase price, financing structure, valuation, expected closing date or the specific assets included in the unit.
The talks follow J&J’s broader effort to focus its portfolio, but the report does not establish whether the discussions are exclusive or advanced. No signed agreement or commitment to transact was reported, so the situation remains subject to negotiations and potential approval requirements.
For Apollo Global, the direct mechanism is capital deployment into a healthcare business that could generate future fee or investment income, depending on the transaction structure. For J&J, a sale would potentially simplify the portfolio and provide proceeds, but the report does not say how the unit contributes to revenue or earnings today.
The main uncertainty is that Bloomberg’s report, as summarized by Investing.com, contains no terms and does not establish that a deal will close. Apollo’s FY2025 revenue was $32.0B, up 22.7% year over year, with a 10.6% net margin and $5.54 diluted EPS; those figures provide scale but do not quantify the effect of this potential acquisition.
The next useful milestones are confirmation of a signed agreement, disclosure of the assets and price, and Apollo’s next earnings update for any effect on deployment, financing or fee-related earnings. J&J’s comments on proceeds and portfolio strategy would also clarify the seller’s rationale.
APO faces a mixed setup: the J&J orthopedics talks could add a new healthcare deployment opportunity, but absent terms the transaction and execution risks remain unpriced.
The implication for APO turns on deal quality rather than the headline alone: a signed transaction at attractive terms could expand capital deployment, while an expensive or heavily financed purchase could dilute the benefit. With no price, structure, assets or closing timetable reported, the evidence does not support a directional equity call.
The talks could end without a transaction, or disclosed terms could show an unattractive price, financing burden or limited earnings contribution.
CoverageSource: Investing.com · Published here FRI, SEP 11 · 7:00 PM ET · the only report in this recordHow this is decided →
STOCK PHOTO · MAURÍCIO MASCAROEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Apollo’s FY2025 revenue rose 22.7% to $32.0B, and acquiring a healthcare asset could extend its capital-deployment pipeline if the terms are favorable.
The report gives no valuation, financing terms or closing certainty, leaving the potential transaction’s earnings impact entirely unestablished.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →